ReproCell Co., Ltd.
Basic information
- Head office
- 9th floor, MetLife Shin-Yokohama Building, 8-11 Shin-Yokohama 3-chome, Kōhoku-ku, Yokohama, Kanagawa Prefecture
- Chief executive
- Shuichi Yokoyama
- Capital
- 2,720,000,000 (27 100 million)
- Employees (non-consolidated)
- 28 people
- Employees (consolidated)
- 101 people
- Start date
- 2003-02-26
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| BioServe | ||||||||
| Cell Innovation Partners | ||||||||
| REPROCELL INDIA | ||||||||
| Reinnervate | ||||||||
| Stemgent | ||||||||
| Steminent社 | ||||||||
| Keio University | ||||||||
| 株式会社MAGiQセラピューティクス |
Network
History
ReproCell Co., Ltd. was established as a regenerative medicine venture originating from Kyoto University and the University of Tokyo.![]()
ReproCell Co., Ltd. was established in 2003 as a regenerative medicine venture originating from Kyoto University and the University of Tokyo.![]()
Established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd., focusing on next-generation drug discovery and medical business.![]()
In February 2014, established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd.![]()
Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment Co., Ltd.![]()
Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment.![]()
Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan.![]()
Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan and began developing regenerative medicine products utilizing iPS cell-derived glial progenitor cells.![]()
Commenced administration to the first subject in Phase II clinical trials and completed the trial in May 2022.![]()
News
There is no news.
Public records
National Tax Agency basic information2020001086778
- Trade name
- 株式会社リプロセル
- Trade name (kana)
- リプロセル
- Name in English
- Corporation type
- 301
- Address
- 〒222-0033 神奈川県横浜市港北区新横浜3丁目8番11号
- Postal code
- 2220033
- Prefecture code
- 14
- City code
- 109
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-10-03
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 2657151
METI gBizINFO2020001086778
- Corporate number
- 2020001086778
- Trade name
- 株式会社リプロセル
- Trade name (kana)
- リプロセル
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 神奈川県横浜市港北区新横浜3丁目8番11号
- Postal code
- 2220033
- Prefecture
- 神奈川県
- Prefecture code
- 14
- City or district
- 横浜市港北区
- City code
- 109
- Street address
- 新横浜3丁目8番11号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 横山 周史
- Capital
- 2720149000
- Employees
- 30
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-10-03
- Key information
- 2020001086778